TNFRSF17 and neoplasm: T-cell engaging bispecific antibody, with unique selective activating anti-CD3 moiety, two heavy-chain-only anti-BCMA moieties for a 2:1 tumor associated antigen to CD3 stoichiometry, with an IgG4 silenced backbone to reduce nonspecific T-cell activation